Alvotech’s Financial Calendar for 2026
Rhea-AI Summary
Alvotech (NASDAQ: ALVO) published its 2026 financial calendar with scheduled dates for interim and annual results, investor calls and the annual general meeting. Results are released after U.S. market close and an investor call follows the next day.
- Mar 18, 2026 – Q4 2025 / full-year 2025 results
- May 6, 2026 – Q1 2026 results
- Jun 3, 2026 – Annual General Meeting (Luxembourg)
- Aug 19, 2026 – Q2 2026 / first six months
- Nov 11, 2026 – Q3 2026 / first nine months
- Mar 10, 2027 – Q4 2026 / full-year 2026
All dates are subject to change. Investor relations contacts were provided for follow-up.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALVO gained 0.82%, reflecting a mild positive market reaction. This price movement added approximately $13M to the company's valuation, bringing the market cap to $1.54B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers in Specialty & Generic pharma were mixed: SUPN up 5.28%, BHC up 1.18%, HCM up 1.57%, while ANIP and INDV were modestly down. No clear, unified sector move around this scheduling news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 19 | Biosimilar settlement | Positive | +3.6% | Settlement with Regeneron enabling potential U.S. launch of AVT06. |
| Dec 17 | Convertible bond financing | Positive | -0.8% | USD 108M senior unsecured convertible bonds to fund R&D and launches. |
| Dec 16 | Financing and guidance | Positive | -6.7% | USD 100M bond launch plus detailed 2025–2026 revenue and EBITDA guidance. |
| Nov 24 | EU approval AVT03 | Positive | +6.4% | European Commission approval of AVT03 denosumab biosimilar across EEA. |
| Nov 20 | EU approval Gobivaz | Positive | -3.3% | EEA marketing authorizations for Gobivaz®, a Simponi biosimilar. |
Recent news skewed positive (approvals, partnerships, financing), but price reactions have been mixed, with several instances of shares declining on otherwise constructive updates.
Over the last few months, Alvotech reported multiple strategic milestones. A Q4 2026 U.S. entry window for AVT06 and approvals for AVT03 and Gobivaz® in the EEA expanded its biosimilar footprint. Financing via USD 108 million convertible bonds and a prior USD 100 million offering supported R&D and global launches through 2026, alongside revenue and EBITDA guidance for 2025–2026. Against this backdrop, the new 2026–2027 financial calendar simply schedules when investors will see these developments translated into reported results.
Market Pulse Summary
This announcement sets out Alvotech’s 2026–2027 financial reporting and AGM schedule, specifying when quarterly and full-year results are planned and when investor calls occur. For investors tracking prior milestones—like recent biosimilar approvals, financing transactions and guidance updates—these dates mark key checkpoints for assessing execution progress and financial impact. Attention will likely focus on how revenue, EBITDA and launch timelines evolve across these scheduled reporting periods.
AI-generated analysis. Not financial advice.
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the following day, after release of the results.
March 18, 2026: Q4 2025 – full-year 2025
May 6, 2026: Q1 2026
August 19, 2026: Q2 2026 – first six months
November 11, 2026: Q3 2026 – first nine months
March 10, 2027: Q4 2026 – full-year 2026
June 3, 2026: Annual General Meeting (held in Luxembourg)
Please note that all dates are subject to change.
Alvotech Investor Relations
Balaji Prasad (US)
Benedikt Stefánsson, VP (IS)
Patrik Ling, VP (SE)
alvotech.ir@alvotech.com
FAQ
When will Alvotech (ALVO) release its Q4 2025 and full-year 2025 results?
On what date is Alvotech's (ALVO) Annual General Meeting in 2026?
When will Alvotech (ALVO) report Q1 2026 results and when is the investor call?
What are the dates for Alvotech's (ALVO) midyear and Q3 2026 reports?
Will Alvotech (ALVO) hold investor calls after each results release in 2026?
Are Alvotech's (ALVO) 2026 financial calendar dates final?
